Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2011 (2011), Article ID 896040, 9 pages
http://dx.doi.org/10.1155/2011/896040
Clinical Study

Time to and Predictors of CD4+ T-Lymphocytes Recovery in HIV-Infected Children Initiating Highly Active Antiretroviral Therapy in Ghana

1Department of Child Health, University of Ghana Medical School, Accra, Ghana
2University of Medicine and Dentistry of New Jersey, Piscataway, NJ 08854-8021, USA
3Yale Center for Analytical Sciences, Yale University School of Medicine, New Haven, CT 06510-3206, USA
4Departments of Pediatrics and Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510-3206, USA

Received 26 January 2011; Revised 24 February 2011; Accepted 3 March 2011

Academic Editor: Eric Daar

Copyright © 2011 Lorna Renner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. M. Schnittman, H. C. Lane, J. Greenhouse, J. S. Justement, M. Baseler, and A. S. Fauci, “Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 16, pp. 6058–6062, 1990. View at Publisher · View at Google Scholar · View at Scopus
  2. R. S. Veazey, M. DeMaria, L. V. Chalifoux et al., “Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection,” Science, vol. 280, no. 5362, pp. 427–431, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Vlahov, N. Graham, D. Hoover et al., “Prognostic indicators for AIDS and infectious disease death in HIV- infected injection drug users: plasma viral load and CD4+ cell count,” Journal of the American Medical Association, vol. 279, no. 1, pp. 35–40, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Nishanian, J. M. G. Taylor, B. Manna et al., “Accelerated changes (inflection points) in levels of serum immune activation markers and CD4+ and CD8+ T cells prior to AIDS onset,” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 18, no. 2, pp. 162–170, 1998. View at Google Scholar · View at Scopus
  5. G. Pantaleo, C. Graziosi, and A. S. Fauci, “Mechanisms of disease: the immunopathogenesis of human immunodeficiency virus infection,” The New England Journal of Medicine, vol. 328, no. 5, pp. 327–335, 1993. View at Publisher · View at Google Scholar · View at Scopus
  6. J. W. Mellors, A. Muñoz, J. V. Giorgi et al., “Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection,” Annals of Internal Medicine, vol. 126, no. 12, pp. 946–954, 1997. View at Google Scholar · View at Scopus
  7. S. Diagbouga, C. Chazallon, M. D. Kazatchkine et al., “Successful implementation of a low-cost method for enumerating CD4+ T lymphocytes in resource-limited settings: the ANRS 12-26 study,” AIDS, vol. 17, no. 15, pp. 2201–2208, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Mandy, G. Janossy, M. Bergeron, R. Pilon, and S. Faucher, “Affordable CD4+ T-cell enumeration for resource-limited regions: a status report for 2008,” Cytometry B, vol. 74, supplement 1, pp. S27–S39, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. B. O. Taiwo and R. L. Murphy, “Clinical applications and availability of CD4+ T cell count testing in sub-Saharan Africa,” Cytometry B, vol. 74, supplement 1, pp. S11–S18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Katzenstein, M. Laga, and J. P. Moatti, “The evaluation of the HIV/AIDS drug access initiatives in Côte D'ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa,” AIDS, vol. 17, supplement 3, pp. S1–S4, 2003. View at Google Scholar · View at Scopus
  11. R. Song, J. Jelagat, D. Dzombo et al., “Efficacy of highly active antiretroviral therapy in HIV-1-infected children in Kenya,” Pediatrics, vol. 120, no. 4, pp. e856–e861, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Reddi, S. C. Leeper, A. C. Grobler et al., “Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa,” BMC Pediatrics, vol. 7, p. 13, 2007. View at Google Scholar
  13. T. Puthanakit, A. Oberdorfer, N. Akarathum et al., “Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program,” Clinical Infectious Diseases, vol. 41, no. 1, pp. 100–107, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Puthanakit, S. J. Kerr, J. Ananworanich, T. Bunupuradah, P. Boonrak, and V. Sirisanthana, “Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy,” Pediatric Infectious Disease Journal, vol. 28, no. 6, pp. 488–492, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Kumarasamy, K. K. Venkatesh, B. Devaleenol, S. Poongulali, S. N. Moothi, and S. Solomon, “Safety, tolerability and effectiveness of generic HAART in HIV-Infected children in South India,” Journal of Tropical Pediatrics, vol. 55, no. 3, pp. 155–159, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Janssens, B. Raleigh, S. Soeung et al., “Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia,” Pediatrics, vol. 120, no. 5, pp. e1134–e1140, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. E. George, F. Noël, G. Bois et al., “Antiretroviral therapy for HIV-1-infected children in Haiti,” Journal of Infectious Diseases, vol. 195, no. 10, pp. 1411–1418, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Bolton-Moore, M. Mubiana-Mbewe, R. A. Cantrell et al., “Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia,” Journal of the American Medical Association, vol. 298, no. 16, pp. 1888–1899, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Paintsil, M. Ghebremichael, S. Romano, and W. A. Andiman, “Absolute CD4+ T-lymphocyte count as a surrogate marker of pediatric human immunodeficiency virus disease progression,” Pediatric Infectious Disease Journal, vol. 27, no. 7, pp. 629–635, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. A. M. Wade and A. E. Ades, “Incorporating correlations between measurements into the estimation of age-related reference ranges,” Statistics in Medicine, vol. 17, no. 17, pp. 1989–2002, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. D. S. Stein, J. A. Korvick, and S. H. Vermund, “CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review,” Journal of Infectious Diseases, vol. 165, no. 2, pp. 352–363, 1992. View at Google Scholar · View at Scopus
  22. M. W. Kline, S. Rugina, M. Ilie et al., “Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy,” Pediatrics, vol. 119, no. 5, pp. e1116–e1120, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. D. P. O'Brien, D. Sauvageot, D. Olson et al., “Treatment outcomes stratified by baseline immunological status among young children receiving nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings,” Clinical Infectious Diseases, vol. 44, no. 9, pp. 1245–1248, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. C. H. Soh, J. M. Oleske, M. T. Brady et al., “Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents,” Lancet, vol. 362, no. 9401, pp. 2045–2051, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. R. D. Moore and J. C. Keruly, “CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression,” Clinical Infectious Diseases, vol. 44, no. 3, pp. 441–446, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. C. G. Sutcliffe, J. H. van Dijk, C. Bolton, D. Persaud, and W. J. Moss, “Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa,” The Lancet Infectious Diseases, vol. 8, no. 8, pp. 477–489, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. A. S. Walker, K. Doerholt, M. Sharland, and D. M. Gibb, “Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study,” AIDS, vol. 18, no. 14, pp. 1915–1924, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. M. R. Kamya, H. Mayanja-Kizza, A. Kambugu et al., “Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy,” Journal of Acquired Immune Deficiency Syndromes, vol. 46, no. 2, pp. 187–193, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Nicastri, C. Angeletti, L. Palmisano et al., “Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy,” AIDS, vol. 19, no. 6, pp. 577–583, 2005. View at Google Scholar · View at Scopus
  30. A. L. Moore, A. Mocroft, S. Madge et al., “Gender differences in virologic response to treatment in an HIV-positive population: a cohort study,” Journal of Acquired Immune Deficiency Syndromes, vol. 26, no. 2, pp. 159–163, 2001. View at Google Scholar · View at Scopus
  31. D. W. Notermans, N. G. Pakker, D. Hamann et al., “Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults,” Journal of Infectious Diseases, vol. 180, no. 4, pp. 1050–1056, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Staszewski, V. Miller, C. Sabin et al., “Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy,” AIDS, vol. 13, no. 8, pp. 951–956, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. F. García, E. De Lazzari, M. Plana et al., “Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count,” Journal of Acquired Immune Deficiency Syndromes, vol. 36, no. 2, pp. 702–713, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Brogly, P. Williams, G. R. Seage III, J. M. Oleske, R. Van Dyke, and K. McIntosh, “Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice,” Journal of the American Medical Association, vol. 293, no. 18, pp. 2213–2220, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. R. M. Gulick, J. W. Mellors, D. Havlir et al., “Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy,” The New England Journal of Medicine, vol. 337, no. 11, pp. 734–739, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. S. M. Hammer, M. S. Saag, M. Schechter et al., “Treatment for adult HIV infection: 2006 Recommendations of the International AIDS Society-USA panel,” Journal of the American Medical Association, vol. 296, no. 7, pp. 827–843, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. W. A. O'Brien, P. M. Hartigan, E. S. Daar, M. S. Simberkoff, and J. D. Hamilton, “Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS,” Annals of Internal Medicine, vol. 126, no. 12, pp. 939–945, 1997. View at Google Scholar
  38. G. R. Kaufmann, H. Furrer, B. Ledergerber et al., “Characteristics, determinants, and clinical relevance of CD4+ T cell recovery to <500 cells/μL in HIV type 1-infected individuals receiving potent antiretroviral therapy,” Clinical Infectious Diseases, vol. 41, no. 3, pp. 361–372, 2005. View at Publisher · View at Google Scholar · View at Scopus